Adverse events in analgesic treatment with tramadol associated with CYP2D6 extensive-metaboliser and OPRM1 high-expression variants

Annals of the Rheumatic Diseases

Volumn 69, Issue 10, 2010, Pages 1889-1890

  Kim, Eunjin ^a   Choi, Chan Bum ^b   Kang, Changwon ^a   Bae, Sang Cheol ^b  

^a Korea Advanced Institute of Science and Technology (KAIST)   (South Korea)

^b Hanyang University Hospital for Rheumatic Diseases   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450 2D6; MU 1 OPIATE RECEPTOR; MU OPIATE RECEPTOR; PARACETAMOL; TRAMADOL; UNCLASSIFIED DRUG; NARCOTIC ANALGESIC AGENT; OPRM1 PROTEIN, HUMAN;

CONTROLLED STUDY; GENE EXPRESSION; GENETIC ASSOCIATION; GENETIC VARIABILITY; GENOTYPE; HUMAN; KNEE OSTEOARTHRITIS; LETTER; MAJOR CLINICAL STUDY; NAUSEA; PRIORITY JOURNAL; VOMITING; CHEMICALLY INDUCED; GENETIC PREDISPOSITION; GENETICS;

ANALGESICS, OPIOID; CYTOCHROME P-450 CYP2D6; GENETIC PREDISPOSITION TO DISEASE; HUMANS; NAUSEA; RECEPTORS, OPIOID, MU; TRAMADOL; VOMITING;

EID: 77957269570     PISSN: 00034967     EISSN: 14682060     Source Type: Journal    
DOI: 10.1136/ard.2009.124347     Document Type: Letter

References (10)

1. Cossmann M, Kohnen C, Langford R, et al. [Tolerance and safety of tramadol use. Results of international studies and data from drug surveillance]. Drugs 1997;53 Suppl 2:50-62.
2. Gan TJ. Mechanisms underlying postoperative nausea and vomiting and neurotransmitter receptor antagonist-based pharmacotherapy. CNS Drugs 2007;21:813-33.
3. Subrahmanyam V, Renwick AB, Walters DG, et al. Identification of cytochrome P-450 isoforms responsible for cis-tramadol metabolism in human liver microsomes. Drug Metab Dispos 2001;29:1146-55.
4. Gillen C, Haurand M, Kobelt DJ, et al. Affinity, potency and efficacy of tramadol and its metabolites at the cloned human mu-opioid receptor. Naunyn Schmiedebergs Arch Pharmacol 2000;362:116-21.
5. Ingelman-Sundberg M, Sim SC, Gomez A, et al. Influence of cytochrome P450 polymorphisms on drug therapies: pharmacogenetic, pharmacoepigenetic and clinical aspects. Pharmacol Ther 2007;116:496-526.
6. Zhang Y, Wang D, Johnson AD, et al. Allelic expression imbalance of human mu opioid receptor (OPRM1) caused by variant A118G. J Biol Chem 2005;280:32618-24.
7. Choi CB, Song JS, Kang YM, et al. A 2-week, multicenter, randomized, double-blind, double-dummy, add-on study of the effects of titration on tolerability of tramadol/ acetaminophen combination tablet in Korean adults with knee osteoarthritis pain. Clin Ther 2007;29:1381-9.
8. Sheng HH, Zeng AP, Zhu WX, et al. Allelic distributions of CYP2D6 gene copy number variation in the Eastern Han Chinese population. Acta Pharmacol Sin 2007;28:279-86.
9. Gaedigk A, Simon SD, Pearce RE, et al. The CYP2D6 activity score: translating genotype information into a qualitative measure of phenotype. Clin Pharmacol Ther 2008;83:234-42.
10. Stamer UM, Musshoff F, Kobilay M, et al. Concentrations of tramadol and O-desmethyltramadol enantiomers in different CYP2D6 genotypes. Clin Pharmacol Ther 2007;82:41-7.